$0.066
-0.031 (-46.45%)Zum Schluss
- High
- 0.085
- Open
- 0.065
- VWAP
- 0.07
- Vol
- 266.56M
- Mkt Cap
- 3.12M
- Low
- 0.060
- Amount
- 18.79M
- EV/EBITDA, TTM
- 0.00
Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.
Bewertungskennzahlen
Event-Zeitleiste
News
9.505-21BenzingaWhy Toll Brothers Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
7.505-20SeekingAlphaPetros Pharmaceuticals partners with Innolitics to accelerate SaaS platform development
4.504-29BenzingaUS Stocks Mixed; Coca-Cola Posts Upbeat Earnings
2.003-27TipRanks3 Penny Stocks to Watch Now, 3/27/25
8.503-26BenzingaNasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion
PTPI FAQ — answered by Alphio AI
Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.